PHARES Study: Management of Resistant Hypertension
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00224549 |
Recruitment Status :
Completed
First Posted : September 23, 2005
Last Update Posted : February 28, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension | Drug: irbesartan, amlodipine and hydrochlorothiazide | Phase 4 |
Tested hypothesis: For essential resistant hypertension, a new regimen based on intensive RAS blockage is non inferior to the recommended regimen based on intensive sodium depletion.
Primary objective: To demonstrate non-inferiority (i.e difference between the two regimen less than 5 mmHg for the mean day-time SBP at week 12)
- One treatment arm including irbesartan 300 mg, hydrochlorothiazide (HCTZ) 12.5mg, amlodipine 5 mg, ramipril 10mg and bisoprolol 10 mg
- One treatment arm including irbesartan 300 mg, HCTZ 12.5mg, amlodipine 5 mg, spironolactone 25 mg, furosemide 40 mg and amiloride 5 mg.
Secondary objectives:
- To assess clinical and biological safety and efficacy of these regimen
- To evaluate predicted factors of controlled or uncontrolled BP
- To evaluate compliance to treatment
- To compare the cost of the different strategies
- To compare the two strategies in terms of endothelial function and left ventricular diastolic filling
Study design:
- Period 1 from week-4 to week 0 : 4-week treatment for all patients with irbesartan 300 mg, HCTZ 12.5mg, amlodipine 5 mg. At the end of this period, an ABPM will be performed: only patients with a mean day time SBP>135 and/or DBP>85 mmHg will be randomized for a further 3 months treatment
- Period 2 from week 0 to week 4: patients will be randomized in two groups, the first one receiving spironolactone 25mg and the second one receiving ramipril 5 mg as add-on therapy (on top of the previous tri-therapy).
- Period 3 from week 4 to week 8: Patients with BP controlled at week 4 (i.e mean home blood pressure measurement (HBPM) <135/85 mmHg at week 4) remain on the same treatment. For those uncontrolled (i.e. mean HBPM >135/85 mmHg at week 4), furosemide 20 mg will be added in the first group and ramipril will be titrated to 10 mg in the second group
- Period 4 from week 8 to week 10: Patients with BP controlled at week 8 (i.e. mean HBPM <135/85 mmHg at week 8) remain on the same treatment. For those uncontrolled (i.e. mean HBPM >135/85 mmHg at week 8), furosemide will be titrated to 40 mg in the first group and bisoprolol 5 mg will be added in the second group.
- Period 5 from week 10 to week 12 (end of the study): Patients with BP controlled at week 10 (i.e mean HBPM <135/85 mmHg at week 10) remain on the same treatment. For those uncontrolled (i.e mean HBPM > 135/85 mmHg at week 10), amiloride 5 mg will be added to the previous treatment in the first group and bisoprolol will be titrated to 10 mg in the second group.
Reasons for treatment discontinuation:
- Patient decision
- Informed consent withdrawal
- SBP>180 mmHg or <100 mmHg (HBPM) whatever the time during the trial
- Adverse events related to treatment or not
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 180 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Management of Resistant Hypertension -Pharmacokinetic Assessment of Different Antihypertensive Regimen -Comparison of Two Treatment Strategies: Increase Sodium Depletion or Combined Blockage of Renin-angiotensin System (RAS) |
Study Start Date : | April 2005 |
Actual Primary Completion Date : | August 2009 |
Actual Study Completion Date : | August 2009 |

- Drug: irbesartan, amlodipine and hydrochlorothiazide
irbesartan, amlodipine and hydrochlorothiazide
- Mean day-time systolic blood pressure (SBP) at week 12, measured with an average blood pressure measurement (ABPM) device [ Time Frame: at week 12 ]Mean day-time systolic blood pressure (SBP) at week 12, measured with an average blood pressure measurement (ABPM) device
- Efficacy: mean day-time diastolic blood pressure (DBP) at week 12, mean 24 hours SBP and DBP at week 12 measured with an ABPM device [ Time Frame: at week 12, ]hours SBP and DBP at week 12 measured with an ABPM device
- Safety and tolerability: [ Time Frame: during the study ]Safety and tolerability:
- During the study BP will be evaluated every 4 weeks by home blood pressure measurement [HBPM] in order to detect hypotension) [ Time Frame: every 4 weeks ]During the study BP will be evaluated every 4 weeks by home blood pressure measurement [HBPM] in order to detect hypotension)
- Biological examinations: [ Time Frame: during the study ]Biological examinations:
- blood and urinary electrolytes with creatinemia at week 0, 4, 8, 10 and 12 [ Time Frame: at week 0, 4, 8, 10 and 12 ]blood and urinary electrolytes with creatinemia at week 0, 4, 8, 10 and 12
- brain natriuretic peptide (BNP), active renin, aldosterone at week 0 and 12 [ Time Frame: at week 0 and 12 ]brain natriuretic peptide (BNP), active renin, aldosterone at week 0 and 12
- Other explorations: [ Time Frame: during ]Other explorations:
- Treatment compliance (study drug accounting, N-acetyl-seryl-aspartyl-lysyl-proline [Ac SDKP] for angiotensin converting enzyme inhibitor [ACEi]) [ Time Frame: during the study ]Treatment compliance (study drug accounting, N-acetyl-seryl-aspartyl-lysyl-proline [Ac SDKP] for angiotensin converting enzyme inhibitor [ACEi])
- Echocardiography (week 0 and 12) [ Time Frame: week 0 and 12 ]Echocardiography (week 0 and 12)
- Endothelial function (week 0 and 12) [ Time Frame: week 0 and 12 ]Endothelial function (week 0 and 12)
- Pharmacokinetics of drugs (week 0 and 12) [ Time Frame: week 0 and 12 ]Pharmacokinetics of drugs (week 0 and 12)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Primary hypertension
- Resistant hypertension defined by mean day-time SBP > 135 mmHg and DBP > 85 mmHg (determined with ABPM device) after a standardized 4-week regimen including irbesartan, amlodipine and HCTZ.
Exclusion Criteria:
- Secondary hypertension
- Unstable angina, history of stroke or coronary heart disease (coronary by-pass or angioplasty) in the previous 3 months
- History of cough with ACEi or gynecomastia with antialdosterones
- Heart failure (New York Heart Association [NYHA] III-IV)
- Contraindication to beta blockers because of bronchopathy or auriculoventricular block
- Diabetes mellitus (type 1 or 2) with HbA1C > 8%
- Renal failure with creatinine clearance < 40ml/min (COCKROFT evaluation)
- Arm circumference > 42 cm

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00224549
France | |
Investigation Clinical Center European Georges Pompidou Hospital | |
Paris, Ile de France, France, 75015 |
Principal Investigator: | Guillaume BOBRIE, MD | Assistance Publique - Hôpitaux de Paris |
Responsible Party: | Zakia IDIR, Department of Clinical Research of developpement |
ClinicalTrials.gov Identifier: | NCT00224549 |
Other Study ID Numbers: |
P040407 |
First Posted: | September 23, 2005 Key Record Dates |
Last Update Posted: | February 28, 2011 |
Last Verified: | March 2007 |
Resistant hypertension Combined diuretic therapy Combined RAS blockers |
Hypertension Vascular Diseases Cardiovascular Diseases Amlodipine Hydrochlorothiazide Irbesartan Antihypertensive Agents Calcium Channel Blockers Membrane Transport Modulators |
Molecular Mechanisms of Pharmacological Action Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Vasodilator Agents Diuretics Natriuretic Agents Sodium Chloride Symporter Inhibitors Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists |